RAC 2.73% $1.61 race oncology ltd

Speculative M&A Transaction Analysis, page-778

  1. 697 Posts.
    lightbulb Created with Sketch. 121
    I agree with your post @bellmatic but i am not sure that i agree with your last comment "The longer we drag this out, the more that can go wrong folks".

    I would of thought that the longer we go, the more we are de-risking the drug as well as finding more medical benefits it is able to used for and more valuable.
    I am not medical minded but just my thoughts, I may be totally wrong here.
 
watchlist Created with Sketch. Add RAC (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.